Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care

B Glintborg, T Kringelbach, N Bolstad, D J Warren, G Eng, I J Sørensen, A G Loft, O Hendricks, Imj Hansen, A Linauskas, H Nordin, S Kristensen, H Lindegaard, D V Jensen, G L Goll, E Høgdall, J Gehin, C Enevold, C H Nielsen, N S Krogh & 2 andre J S Johansen, M L Hetland

Publikation: Bidrag til tidsskriftLetterForskningpeer review

OriginalsprogEngelsk
TidsskriftScandinavian Journal of Rheumatology
Vol/bind47
Udgave nummer5
Sider (fra-til)418-421
ISSN0300-9742
DOI
StatusUdgivet - sep. 2018

Citer dette

Glintborg, B., Kringelbach, T., Bolstad, N., Warren, D. J., Eng, G., Sørensen, I. J., ... Hetland, M. L. (2018). Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care. Scandinavian Journal of Rheumatology, 47(5), 418-421. https://doi.org/10.1080/03009742.2017.1376110
Glintborg, B ; Kringelbach, T ; Bolstad, N ; Warren, D J ; Eng, G ; Sørensen, I J ; Loft, A G ; Hendricks, O ; Hansen, Imj ; Linauskas, A ; Nordin, H ; Kristensen, S ; Lindegaard, H ; Jensen, D V ; Goll, G L ; Høgdall, E ; Gehin, J ; Enevold, C ; Nielsen, C H ; Krogh, N S ; Johansen, J S ; Hetland, M L. / Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care. I: Scandinavian Journal of Rheumatology. 2018 ; Bind 47, Nr. 5. s. 418-421.
@article{7c9ea69d1e62409ebeae95c15888b00f,
title = "Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care",
keywords = "Adult, Aged, Antibodies, Monoclonal/blood, Antibodies/blood, Arthritis/blood, Denmark, Female, Follow-Up Studies, Humans, Infliximab/administration & dosage, Male, Middle Aged",
author = "B Glintborg and T Kringelbach and N Bolstad and Warren, {D J} and G Eng and S{\o}rensen, {I J} and Loft, {A G} and O Hendricks and Imj Hansen and A Linauskas and H Nordin and S Kristensen and H Lindegaard and Jensen, {D V} and Goll, {G L} and E H{\o}gdall and J Gehin and C Enevold and Nielsen, {C H} and Krogh, {N S} and Johansen, {J S} and Hetland, {M L}",
year = "2018",
month = "9",
doi = "10.1080/03009742.2017.1376110",
language = "English",
volume = "47",
pages = "418--421",
journal = "Scandinavian Journal of Rheumatology",
issn = "0300-9742",
publisher = "Taylor & Francis",
number = "5",

}

Glintborg, B, Kringelbach, T, Bolstad, N, Warren, DJ, Eng, G, Sørensen, IJ, Loft, AG, Hendricks, O, Hansen, I, Linauskas, A, Nordin, H, Kristensen, S, Lindegaard, H, Jensen, DV, Goll, GL, Høgdall, E, Gehin, J, Enevold, C, Nielsen, CH, Krogh, NS, Johansen, JS & Hetland, ML 2018, 'Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care', Scandinavian Journal of Rheumatology, bind 47, nr. 5, s. 418-421. https://doi.org/10.1080/03009742.2017.1376110

Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care. / Glintborg, B; Kringelbach, T; Bolstad, N; Warren, D J; Eng, G; Sørensen, I J; Loft, A G; Hendricks, O; Hansen, Imj; Linauskas, A; Nordin, H; Kristensen, S; Lindegaard, H; Jensen, D V; Goll, G L; Høgdall, E; Gehin, J; Enevold, C; Nielsen, C H; Krogh, N S; Johansen, J S; Hetland, M L.

I: Scandinavian Journal of Rheumatology, Bind 47, Nr. 5, 09.2018, s. 418-421.

Publikation: Bidrag til tidsskriftLetterForskningpeer review

TY - JOUR

T1 - Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care

AU - Glintborg, B

AU - Kringelbach, T

AU - Bolstad, N

AU - Warren, D J

AU - Eng, G

AU - Sørensen, I J

AU - Loft, A G

AU - Hendricks, O

AU - Hansen, Imj

AU - Linauskas, A

AU - Nordin, H

AU - Kristensen, S

AU - Lindegaard, H

AU - Jensen, D V

AU - Goll, G L

AU - Høgdall, E

AU - Gehin, J

AU - Enevold, C

AU - Nielsen, C H

AU - Krogh, N S

AU - Johansen, J S

AU - Hetland, M L

PY - 2018/9

Y1 - 2018/9

KW - Adult

KW - Aged

KW - Antibodies, Monoclonal/blood

KW - Antibodies/blood

KW - Arthritis/blood

KW - Denmark

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Infliximab/administration & dosage

KW - Male

KW - Middle Aged

U2 - 10.1080/03009742.2017.1376110

DO - 10.1080/03009742.2017.1376110

M3 - Letter

VL - 47

SP - 418

EP - 421

JO - Scandinavian Journal of Rheumatology

JF - Scandinavian Journal of Rheumatology

SN - 0300-9742

IS - 5

ER -